Clinical features of SCA36
A novel spinocerebellar ataxia with motor neuron involvement (Asidan)
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To characterize the phenotype of spinocerebellar ataxia type 36 (SCA36), a novel dominant disorder (nicknamed “Asidan”) caused by a hexanucleotide GGCCTG repeat expansion in intron 1 of the NOP56 gene.
Methods: We investigated the clinical, genetic, and neuropathologic characteristics of 18 patients with SCA36. We performed histologic evaluation of a muscle biopsy specimen from 1 patient with SCA36, and neuropathologic evaluation of an autopsied brain from another patient with SCA36.
Results: The (GGCCTG)n expansion was found in 18 ataxic patients from 9 families. The age at onset of ataxia was 53.1 ± 3.4 years, with the most frequent symptoms being truncal ataxia (100% of patients), ataxic dysarthria (100%), limb ataxia (93%), and hyperreflexia (79%). Tongue fasciculation and subsequent atrophy were found in 71% of cases, particularly in those of long duration. Skeletal muscle fasciculation and atrophy of the limbs and trunk were found in 57% of cases. Lower motor involvement was confirmed by EMG and muscle biopsy. The neuropathologic study revealed significant cerebellar Purkinje cell degeneration with obvious loss of lower motor neurons. Immunohistochemical analysis showed that NOP56 was localized to the nuclei of various neurons. Cytoplasmic or intranuclear inclusion staining of NOP56, TDP-43, and ataxin-2 was not observed in the remaining neurons.
Conclusions: This is the first description of the unique clinical features of SCA36, a relatively pure cerebellar ataxia with progressive motor neuron involvement. Thus, SCA36 is a disease that stands at the crossroads of SCA and motor neuron disease.
GLOSSARY
- ALS=
- amyotrophic lateral sclerosis;
- CMAP=
- compound muscle action potential;
- eZIS=
- easy Z-score imaging system;
- H&E=
- hematoxylin & eosin;
- MCP=
- middle cerebellar peduncle;
- MCV=
- motor nerve conduction velocity;
- NADH-TR=
- nicotinamide adenine dinucleotide-tetrazolium reductase;
- NCS=
- nerve conduction study;
- SARA=
- Scale for Assessment and Rating of Ataxia;
- SCA=
- spinocerebellar ataxia;
- SCV=
- sensory nerve conduction velocity;
- SNAP=
- sensory nerve action potential;
- 99mTc-ECD=
- 99mTc-ethylcysteinate dimer
Footnotes
-
Study funding: Supported in part by Grants-in-Aid for Scientific Research (C) 21591084 (to Y.I.) and Scientific Research (B) 21390267 (to K.A.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by Grants-in-Aid from the Research Committees (Nakano I, Sobue G, Mizusawa H, Nishizawa M, and Sasaki H), the Ministry of Health, Labour and Welfare, Japan (to K.A.).
-
Editorial, page 302
- Received August 13, 2011.
- Accepted December 8, 2011.
- Copyright © 2012 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMNAlexander M. Rossor, Zane Jaunmuktane, Martin N. Rossor et al.Neurology, January 30, 2019 -
Article
Decreased parvalbumin immunoreactivity in surviving Purkinje cells of patients with spinocerebellar ataxia-1P.J.S. Vig, J. D. Fratkin, D. Desaiah et al.Neurology, July 01, 1996 -
Articles
Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred(CAG)n expansion and early premonitory signs and symptomsD. Genis, T. Matilla, V. Volpini et al.Neurology, January 01, 1995 -
ARTICLES
Analysis of spinocerebellar ataxia type 1 (SCA1)-related CAG trinucleotide expansion in JapanT. Kameya, K. Abe, M. Aoki et al.Neurology, August 01, 1995